Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04632771
Other study ID # 1536100
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 19, 2020
Est. completion date February 28, 2022

Study information

Verified date April 2022
Source University of California, Davis
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This pilot aims to generate data that are critical for informing the design of a planned, more detailed study to evaluate the effect of multiple micronutrient (MN)-fortified bouillon cube on biomarkers of nutrient status of women and children. Data collection includes measures of nutritional status and dietary intake among women and children and their households in communities in northern Ghana.


Description:

Background: Micronutrient (MN) deficiencies are severe and widespread in West Africa including Ghana, which contributes to impaired growth and development in children, increased risk of mortality, and low economic productivity in adults. While large-scale intervention programs (including salt iodization and cooking oil and wheat flour fortification) exist, these programs are often not well-monitored, and they often provide only a subset of nutrients or reach only a subset of the deficient population. Bouillon cubes may be an ideal fortification vehicle for delivering micronutrients in West Africa because they are purchased by most households (including rural and poorer households), added to home-made meals and consumed by most members of the household in relatively constant amounts, and they are mainly processed centrally at large scale. However, several important questions must be addressed regarding the extent to which multi-fortified bouillon cubes can address inadequate intake of key micronutrients. Objective: This pilot aims to generate data that are critical for informing the design of a planned, more detailed study to evaluate the effect of multiple micronutrient-fortified bouillon cube on biomarkers of nutrient status of women and children. Methods: This will be a cross-sectional study, which will be conducted in the Kumbungu and Tolon districts in the Northern Region, where a recent survey showed that micronutrient deficiencies were common. Four sets of research activities will be carried out, including: 1. Pilot survey: The investigators will recruit non-pregnant, non-lactating women of reproductive age, WRA (n = 250), children 2-5 years of age (n = 250), and lactating women (n= 250) who will be identified from households in selected communities using the random walk method. Information collected will include anthropometric and micronutrient status, hemoglobin concentration, inflammation, morbidity, household-level food consumption, and individual dietary intakes. 2. Retinol isotope dilution (RID) Pilot Study 1: The investigators will recruit non-pregnant and nonlactating women of reproductive age, WRA (n = 30) from a subset of the same communities as the pilot survey using the random walk method, and quantitatively estimate their total body vitamin A stores after consuming a dose of d6-labelled vitamin A. Total body stores of vitamin A will be estimated at 14 days after dosing. 3. Retinol isotope dilution (RID) Pilot Study 2 (kinetic study): Based on results from RID pilot study 1, the investigators will recruit non-pregnant and non-lactating women of reproductive age, WRA (n = 123) from a subset of the same communities as the pilot survey using the random walk method, to construct a population-level plasma retinol kinetic curve, after consuming a dose of d6-labelled vitamin A. A compartmental model will be fit to the plasma retinol kinetic data to develop population-specific coefficients for the RID prediction equation to quantitatively estimate total body vitamin A stores of WRA in the study population. 4. Formative research: The investigators will (a) conduct focus group discussions on knowledge, attitudes and practices related to salt and bouillon cube use, nutrition and health problems in the community, and micronutrient fortification; (b) perform a market assessment of the availability and cost of fortified, non-fortified and potentially fortifiable foods in the communities; and (c) observe how various local food recipes are prepared, including the types and quantities of ingredients used, and cooking duration and temperature.


Recruitment information / eligibility

Status Completed
Enrollment 995
Est. completion date February 28, 2022
Est. primary completion date February 28, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 2 Years and older
Eligibility Pilot survey Inclusion Criteria: - non-pregnant, non-lactating woman of reproductive age (15-49 years) OR child 2-5 years of age OR non-pregnant lactating woman (4-18 mo post-partum, 15-49 years of age) - signed informed consent by participant (if adult woman) or by at least one parent or guardian (if child) Exclusion Criteria: - severe illness warranting hospital referral - chronic severe medical condition (e.g. malignancy) or congenital anomalies requiring frequent medical attention or potentially inferring with nutritional status - unable to provide informed consent due to impaired decision making abilities (if adult woman, or caretaker of potentially eligible child) - current participation in a clinical trial RID Pilot 1 Inclusion Criteria: - non-pregnant, nonlactating woman of reproductive age (15-49 years) - signed informed consent - planning to remain in the study area for the next 1 month - not planning to become pregnant during the next 1 month Exclusion Criteria: - unable to provide informed consent due to impaired decision making abilities - pregnancy (as ascertained via urine pregnancy test for human chorionic gonadotropin) - severe illness warranting hospital referral - reported fever, vomiting or diarrhea (> 3 liquid or semi-liquid stools in 24h) in 7 d prior to data collection - chronic medical condition (e.g. malignancy, gastrointestinal disease) or congenital anomalies requiring frequent medical attention or potentially inferring with nutritional status - current participation in a clinical trial - hemoglobin concentration <80 g/L on the day of isotope dosing - C-reactive protein concentration > 5 mg/L on the day of isotope dosing - reported use of micronutrient supplements that contain vitamin A more than 1 time/wk in the past 30 days RID Pilot 2 Inclusion Criteria: - non-pregnant, nonlactating woman of reproductive age (15-49 years) - signed informed consent - planning to remain in the study area for the next 4 months - not planning to become pregnant during the next 4 months Exclusion Criteria: - unable to provide informed consent due to impaired decision making abilities - pregnancy (as ascertained via urine pregnancy test for human chorionic gonadotropin) - severe illness warranting hospital referral - reported fever, vomiting or diarrhea (> 3 liquid or semi-liquid stools in 24h) in 7 d prior to data collection - chronic medical condition (e.g. malignancy, gastrointestinal disease) or congenital anomalies requiring frequent medical attention or potentially inferring with nutritional status - current participation in a clinical trial - hemoglobin concentration <80 g/L on the day of isotope dosing - C-reactive protein concentration > 5 mg/L on the day of isotope dosing - reported use of micronutrient supplements that contain vitamin A more than 1 time/wk in the past 30 days Formative Research Inclusion Criteria: - Adults (including women, men, and other key community members such as merchants, etc.) - Provision of written informed consent

Study Design


Intervention

Other:
N/A (observational study)
N/A (observational study)

Locations

Country Name City State
Ghana University of Ghana Accra

Sponsors (5)

Lead Sponsor Collaborator
University of California, Davis Helen Keller International, Newcastle University, Penn State University, University of Ghana

Country where clinical trial is conducted

Ghana, 

Outcome

Type Measure Description Time frame Safety issue
Other Micronutrient supplement use Reported use of daily or periodic micronutrient supplements in the past month Day 1
Other Consumption of fruits and vegetables Assessed using the WHO STEPS questionnaire Day 1
Other Consumption of snacks and sweetened beverages Assessed using the WHO STEPS questionnaire Day 1
Other Physical activity Assessed using the WHO STEPS questionnaire Day 1
Other Tobacco use Assessed using the WHO STEPS questionnaire Day 1
Other Alcohol use Assessed using the WHO STEPS questionnaire Day 1
Primary Hemoglobin Hemoglobin concentration in venous blood (g/dL) among women and children Day 1
Primary Iron status Concentrations of iron status biomarkers (serum iron, ferritin, and soluble transferrin receptor) among women and children Day 1
Primary Vitamin A status Concentrations of vitamin A status biomarkers (serum retinol and retinol-binding protein) among women and children Day 1
Primary Vitamin B12 status Concentrations of vitamin B12 in serum among women and children Day 1
Primary Folate status Concentrations of folate in serum (among women and children) and whole blood and erythrocytes (women only) Day 1
Primary Zinc status Serum zinc concentration among women and children Day 1
Primary Breast milk vitamin A concentration Vitamin A concentration in breast milk, expressed per unit volume and per gram fat Day 1
Primary Breast milk vitamin B12 concentration Vitamin B12 concentration in breast milk Day 1
Primary Total body vitamin A stores Distribution of total body vitamin A stores among non-pregnant, non-lactating women, expressed as total mass and per gram of liver, estimated by retinol isotope dilution Day 7
Primary Total body vitamin A stores Distribution of total body vitamin A stores among non-pregnant, non-lactating women, expressed as total mass and per gram of liver, estimated by retinol isotope dilution Day 14
Primary Coefficient "Fa" Defined as the fraction of the oral tracer dose absorbed and retained in stores, estimated by modeling of data on labeled and unlabelled vitamin A in plasma collected using a "Super Woman" design and used to calculate total body stores for individual participants. Blood samples from RID Pilot 2 participants collected at randomly assigned time points over a 90-day time frame
Primary Coefficient "S" Defined as retinol specific activity in plasma/stores at time "t", estimated by modeling of data on labeled and unlabelled vitamin A in plasma collected using a "Super Woman" design and used to calculate total body stores for individual participants. Blood samples from RID Pilot 2 participants collected at randomly assigned time points over a 90-day time frame
Primary Prevalence of anemia and micronutrient deficiencies Prevalence of hemoglobin and micronutrient biomarkers above or below relevant cutoffs Day 1
Primary Urinary iodine concentration Iodine concentration of urine among women and children Day 1
Primary Themes from focus group discussions Perceptions of bouillon and salt use, cooking practices, noncommunicable disease, and other nutrition and diet-related issues Day 1
Primary Recipe ingredients Quantity of each recipe ingredient (including bouillon and salt) used in common local recipes; interpreted in relation to cooking duration and temperature (type and duration, e.g. of boiling) used in common recipes Day 1
Primary Fortified food accessibility Availability, price, and fortification levels of fortified food products in markets Day 1
Secondary Blood pressure Blood pressure measured among women and children (mm Hg, systolic and diastolic) Day 1
Secondary Hypertension Prevalence of blood pressure measurements above cutoffs for hypertension Day 1
Secondary Height, cm Standing height measured among women and children Day 1
Secondary Weight, kg Weight measurement among women and children Day 1
Secondary Waist to hip ratio Waist and hip circumference (measured in cm) among women and their ratio Day 1
Secondary Mid-upper arm circumference, cm Mid-upper arm circumference measured among children Day 1
Secondary Anthropometric Z-scores Z-scores calculated for young children based on WHO growth standards (height-for-age, weight-for-height, height-for-age, BMI-for-age) Day 1
Secondary Prevalence of undernutrition Prevalence of anthropometric Z-scores or mid-upper arm circumference below WHO cutoffs to indicate child undernutrition Day 1
Secondary Prevalence of overweight and obesity Prevalence of body mass index (women) or BMI-for-age Z-score (children) above WHO cutoffs Day 1
Secondary Morbidity symptoms Reported malaria, diarrhea, fever, or vomiting in the past 7 days (all survey participants) Day 1
Secondary Inflammation Serum concentrations of CRP, AGP, amyloid A, MCP-1, IL-6, IL-10, IL-1b, adiponectin Day 1
Secondary Household-food consumption Calculated daily household level consumption and individual apparent consumption of fortified foods (wheat flour, oil, salt) and bouillon estimated using 1-month recall Day 1
Secondary Individual dietary intake Dietary intake of fortified foods and bouillon, measured by 24h recall among a subset of women participating in the survey who also participate in cooking observations Day 1
Secondary Urinary sodium concentration Expressed per unit volume and in relation to urinary creatinine concentration Day 1
Secondary Status of other micronutrients Concentrations of micronutrients in serum and breast milk (vitamins E, B1, B2, B3, B5, B6, B7) Day 1
See also
  Status Clinical Trial Phase
Terminated NCT00801931 - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders Phase 1/Phase 2
Completed NCT02948283 - Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia Phase 1
Completed NCT03341338 - Genes-in-Action - Hepcidin Regulation of Iron Supplementation
Completed NCT00060398 - Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer Phase 3
Recruiting NCT05384691 - Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions Phase 2
Not yet recruiting NCT06309641 - Methemoglobinemia Following Intravenous Iron Treatment
Completed NCT02930850 - Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation N/A
Completed NCT02912494 - A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD) Phase 3
Completed NCT02888171 - Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency N/A
Completed NCT02912533 - A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD) Phase 3
Completed NCT03822884 - Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers Phase 1
Completed NCT02384122 - Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias Phase 3
Completed NCT02603250 - Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda N/A
Completed NCT02176759 - Iron Absorption From Rice Fortified With Ferric Pyrophosphate N/A
Withdrawn NCT01934842 - A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate N/A
Completed NCT02310113 - Transfusion and Skeletal Muscle Tissue Oxygenation N/A
Completed NCT01922479 - Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure Phase 4
Completed NCT01693029 - Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa Phase 3
Completed NCT01458028 - Age and Gender Effects on the Pharmacokinetics of BAY85-3934 Phase 1
Completed NCT01432717 - Study of ACE-536 in Healthy Postmenopausal Women Phase 1